Clinical TrialID 8100
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III
NCT05886829
COVID-19|Symptoms and Signs|COVID-19 Pandemic|Coronavirus Disease 2019|Coronavirus Infections
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 8100
- Evidence Id
- 8100
- Core Evidence Id
- 8100
- Source Clinical Trial Id
- 8099
- Herb2 Clinical Trial Id
- HBCT008099
- Nct Id
- NCT05886829
- Title
- Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III
- Status
- Completed
- Phase
- Phase 2|Phase 3
- Study Result
- No
- Study Condition
- COVID-19|Symptoms and Signs|COVID-19 Pandemic|Coronavirus Disease 2019|Coronavirus Infections
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
- Intervention
- COMBINATION_PRODUCT: Chlorpheniramine Maleate 0.4% Nasal Spray|COMBINATION_PRODUCT: Placebo
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Double
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 157
- Outcome Measure
- Daily symptoms score (DSS), Change from baseline daily symptoms score (DSS) to day 7 The DSS is an instrument comprised of a four-point severity rating scale ranging from 0 to 3. 0 = no symptoms 1. = mild symptoms 2. = moderate symptoms 3. = severe symptoms., Baseline through day 7|Visual Analog Scale (VAS), Change from baseline visual analog scale (VAS) to day 7 The VAS is a quantitative method that evaluates the severity of symptoms on a scale of 1-10 (no signs to worst symptoms). A 10 cm line is used to grade the severity of symptoms from "no symptoms" (0 cm) to "the highest level of symptoms" (10 cm)., Baseline through day 7
- Sponsor Collaborator
- Dr. Ferrer BioPharma|Hospital CEMESA Cortés, San Pedro Sula, Honduras
- Funded By
- INDUSTRY
- Location
- Hospital CEMESA, Cortés, San Pedro Sula, Honduras
- Other Id
- DFB-006
- Start Date
- 2022-07-27
- Primary Completion Date
- 2023-01-19
- Completion Date
- 2023-02-01
- First Posted
- 2023-06-02
- Results First Posted
- Last Update Posted
- 2023-06-02
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05886829
- Title Cn
- Title En
- Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III
- Bilingual Status
- semi_complete